Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) has announced its intention to collaborate with Boston Children’s Hospital. The collaboration is expected to aid in the rapid and precise diagnoses for patients with suspected rare diseases. In collaborating, the duo will engage The Manton Center’s expertise alongside Alexion’s genomics and data sciences capabilities in decoding and treating rare diseases.
According to a geneticist at Boston Children’s Catherine Brownstein who also doubles up as a principal investigator of the project, says that the new move will provide the necessary interventions for diagnoses.
Each of the two partners will play a unique role
The Director of the Manton Center at Boston Children’s Hospital, Alan Beggs outlines, “This partnership combines the unique strengths of each of our organizations to answer critical questions posed by puzzling and difficult diseases.”
Each of the two is playing an exclusive role in supporting the collaboration. Alexion will be sharing its 20 Rare-Disease Questions (20RDQ) platform while the Manton Center and Innovation Accelerator will be tasked with combining 20RDQ with internally integrated software. These contributions will help in creating computable descriptions for patients.
Apparently, Boston Children’s Hospital is a home to the world’s largest research enterprise based at a pediatric medical center. At its formation, it was a 20-bed hospital for children but it is now a 415-bed comprehensive center primarily for pediatric and adolescent health care. On the other hand, Alexion, which focuses on researches and development of core therapies is the leader in complement inhibition.
Data science approaches hold great promise for upcoming diagnoses
Expert clinical insights are required in making a profound difference to patients and their families. Thus, such collaborations are not in vain as John Reynders, the Vice President of Data Sciences at Alexion explains. For sure the artificial intelligence will go a long way in improving and speeding up diagnoses. Besides, it will also provide room for accuracy while creating disease intervention options within a meaningful timeline.
In other news, Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) has launched a patient support initiative, which will be addressing the needs of the rare and debilitating kidney disease C3 glomerulopathy (C3G). The initiative will bring information, resources, and support to patients and families suffering from this illness.